Octreotide therapy for chylothorax in infants and children: A brief review

We review physiology and pharmacology relating to the use of octreotide for chylothorax in infants and children. We review the published experience of octreotide dosing in this context. Systematic review of the literature, including PubMed (English-only journals), citations from relevant articles, m...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric critical care medicine Vol. 7; no. 6; pp. 576 - 579
Main Authors:	Helin, Radley D, Angeles, Sheila Therese V, Bhat, Rama
Format:	Journal Article
Language:	English
Published:	United States 01-11-2006
Subjects:	Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - therapeutic use Child Chylothorax - drug therapy Chylothorax - therapy Humans Infant Infant, Newborn Octreotide - administration & dosage Octreotide - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We review physiology and pharmacology relating to the use of octreotide for chylothorax in infants and children. We review the published experience of octreotide dosing in this context. Systematic review of the literature, including PubMed (English-only journals), citations from relevant articles, major textbooks, and personal files. Octreotide has been used as a successful therapeutic adjunct in a small number of neonatal cases and a larger number of pediatric cases. No consensus has been reached as to the optimal route of administration, dose, duration of therapy, or strategy for discontinuation of therapy. We suggest using higher doses (80-100 microg/kg/day) and initiating therapy early rather than using a low initial dose with upward titration. Duration of therapy required to elicit a significant response may vary between patients.
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Feature-4 ObjectType-Undefined-1 content type line 23 ObjectType-Review-2 ObjectType-Article-3
ISSN:	1529-7535
DOI:	10.1097/01.PCC.0000235256.00265.C8